Your missionThe Josep Carreras Leukaemia Research Institute (IJC) is a comprehensive cancer research center dedicated to conducting research and driving innovation in the epidemiological, preventive, clinical, translational, and basic aspects of leukemia and other hematologic malignancies, with the final aim of finding a cure for these diseases. It was created in 2010 and has experienced exponential growth.
The IJC is part of the network of Excellence Research Centers of Catalonia (CERCA) and was accredited as a Severo Ochoa Center of Excellence by the Ministry of Science, Innovation, and Universities in 2024. Since 2018, the Institute has also been accredited by the Scientific Foundation of the Spanish Association Against Cancer (FCAECC). Additionally, IJC is integrated into the Institut de Recerca Germans Trias i Pujol (IGTP) accreditation as an Accredited Health Research Institute (IIS) by the Carlos III Health Institute (ISCIII).
The IJC's main headquarters is located within the Can Ruti Biomedical Campus, alongside other leading biomedical institutions, providing direct access to cutting-edge scientific and technological facilities, as well as complementary community services. The IJC has six locations integrated into reference hospitals: Hospital Germans Trias i Pujol, Hospital Clínic, Hospital Sant Pau, Hospital Trueta, Hospital del Mar, and Hospital San Joan de Déu. This facilitates close collaboration between basic and clinical researchers, fostering translational research that integrates basic science with clinical practice in clinical settings.
The Josep Carreras Leukemia Research Institute is looking for a Junior Group Leader for our Can Ruti Campus.
RESEARCH DESCRIPTION The Josep Carreras Leukaemia Research Institute (IJC) is an independent biomedical research institute (CERCA) opened by the Catalan Government in 2010. IJC performs biomedical research and personalized medicine in the field of malignant blood diseases, especially leukemia. One of the current priorities of the IJC is the understanding of the molecular basis underlying malignant blood diseases. This basic knowledge is the foundation for implementing new therapeutic strategies to improve patient survival.
Your profileWHAT WE NEED We are seeking applicants with a strong scientific background and an excellent track record in research related to cancer heterogeneity, cellular hierarchies, and tumor microenvironment. Candidates should demonstrate expertise in cutting-edge methodologies such as lineage tracing, in vivo modeling, and transcriptomic analyses including single-cell transcriptomics. A deep interest in understanding the molecular and cellular mechanisms of cancer initiation and progression is essential. Familiarity with studying processes such as cellular plasticity and their role in cancer and therapeutic resistance is highly valued. Applicants should also have experience in leading collaborative, interdisciplinary projects and show evidence of successfully securing competitive research funding as principal investigators. Strong organizational and communication skills, along with a commitment to fostering a collaborative and dynamic research environment, are required.
We will appreciate internal applicants. A Ramon y Cajal grant will be highlighted and valued.
Why us?WHAT WE OFFER A permanent contract linked to scientific evaluations (contract "Investigador/a Distingit/da")Junior Group Leaders at IJC are provided with suitable laboratory space and access to state-of-the-art core facilities at IJC.Be part of a young, collaborative, and international work environment with cutting-edge technologies and interdisciplinary teams of scientists, including experts in medicine, immunology, genomics, and bioinformatics.Core facilities of the IJC include flow cytometry, genomics, proteomics, and the single-cell unit.Exciting and innovative research projects in the fields of leukemia, lymphocyte biology, and associated malignancies.The stimulating environment of the Barcelona metropolitan area. How to apply?DEADLINE FOR APPLICATIONS Please submit your application by December 23th, 2024.
Deadline
#J-18808-Ljbffr